1667-P: Patient-Reported Outcomes in Adults Initiating Treatment with Tirzepatide or Intensified Conventional Care Early in the Course of T2D: Results after Two Years of Treatment in SURPASS-EARLY

作者
Kristina Secnik Boye,Palash Sharma,Arkopal Choudhury,ELISA GOMEZ,SUZANNE E. WILLIAMSON,Vivian Thuyanh Thieu
出处
期刊:Diabetes [American Diabetes Association]
卷期号:75 (Supplement_1)
标识
DOI:10.2337/db26-1667-p
摘要

Introduction and Objective: Tirzepatide (TZP), a GIP/GLP-1 RA, showed superior glycemic control, weight and waist circumference reduction at 2 years vs intensified conventional care (ICC) in adults on metformin treatment in the SURPASS-EARLY trial. We evaluated the HRQoL of adults receiving TZP or ICC in this study. Methods: Adults with T2D, inadequately controlled with diet, exercise, and metformin were randomized (1:1) to QW TZP 15 mg or maximum tolerated dose (MTD) or ICC for 2 years. Changes from baseline to Weeks 56 and 104 were assessed for the IWQOL-Lite-CT, SF-36v2 acute form, APPADL, and IW-SP. Results: Overall, 794 participants with mean age 53.5 years, duration of T2D 2.6 years, HbA1c 7.8%, and BMI 35.4 kg/m2 were randomized. Participants in the TZP 15 mg or MTD group had improved IQWOL-Lite-CT total, SF-36v2 PCS, APPADL total, and IW-SP total scores vs baseline, and vs participants in the ICC group, at Weeks 56 and 104 (all p<0.05; Table). A significant improvement in SF-36v2 MCS score was seen in the TZP 15 mg or MTD group vs baseline (p<0.05) but not vs the ICC group at Week 56. Conclusion: In alignment with the overall results of SURPASS-EARLY, TZP treatment significantly improved overall physical and psychosocial functioning and health, as well as weight-related QoL - specifically the ability to perform daily activities and self-perception - compared with ICC in the trial. Disclosure K.S. Boye: Employee; Current; Lilly. Stock/Shareholder; Current; Lilly. P. Sharma: None. A. Choudhury: Employee; Current; Eli Lilly and Company. E. Gomez: Employee; Current; Eli Lilly and Company. S.E. Williamson: Consultant; Current; Eli Lilly and Company. V. Thieu: None. Funding Eli Lilly and Company (no reference number)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zzw发布了新的文献求助10
刚刚
1秒前
王明阳完成签到 ,获得积分10
2秒前
池载岸完成签到,获得积分10
2秒前
666完成签到,获得积分10
3秒前
3秒前
4秒前
丘比特的应助被wang采纳,获得10
4秒前
5秒前
5秒前
5秒前
5秒前
6秒前
6秒前
6秒前
11ovo的应助被天才刺猬少女采纳,获得10
7秒前
XUANZHEXIA完成签到,获得积分10
7秒前
abccd123完成签到,获得积分10
7秒前
zcyuqing发布了新的文献求助10
7秒前
7秒前
春潮白完成签到,获得积分10
7秒前
xixi发布了新的文献求助10
7秒前
小陆需要帮助完成签到 ,获得积分10
7秒前
酷酷的幼菱完成签到 ,获得积分10
7秒前
阿也完成签到 ,获得积分10
8秒前
华华关注了科研通微信公众号
8秒前
舒心盼曼发布了新的文献求助10
8秒前
dmj发布了新的文献求助10
9秒前
CSL完成签到,获得积分20
9秒前
9秒前
cz发布了新的文献求助10
11秒前
111关注了科研通微信公众号
11秒前
不想写论文完成签到,获得积分10
11秒前
xsss发布了新的文献求助10
11秒前
文艺书雪发布了新的文献求助10
11秒前
luoshoahan发布了新的文献求助10
11秒前
pump发布了新的文献求助10
12秒前
喵了个咪完成签到,获得积分10
12秒前
13秒前
su发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156499
求助须知:如何正确求助?哪些是违规求助? 9552615
关于积分的说明 21710463
捐赠科研通 7745506
什么是DOI,文献DOI怎么找? 3426576
关于科研通互助平台的介绍 2551389
邀请新用户注册赠送积分活动 2470382